EUVIMEDEUVIMED entdecken
Open Access

Multi-omics classification of acute myeloid leukemia guides drug combinations to overcome Venetoclax resistance

Runyu Yang, Hui Feng, Mengyao Zhang, Yi Liu, Minna Luo, Ruimin Liu, Kaiyao Wang, Qijing Li, Wenjuan Wang, Jing Chen, Yue Du, Jiayi Xiao und 3 weitere

Cancer Drug Resistance · 26.03.2026

DOI: 10.20517/cdr.2025.228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Drug Resistance, online erschienen am 26.03.2026. Verfasst von Runyu Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Acute myeloid leukemia (AML) is an aggressive hematological malignancy. Conventional risk stratification in AML fails to predict patient responses to targeted therapies such as Venetoclax, hindering precision medicine and the development of strategies to overcome drug resistance.

Methods

We established an integrated multi-omics framework incorporating messenger RNA (mRNA)/long non-coding RNA (lncRNA) expression, DNA methylation, copy number alterations, and somatic mutation data. Using nine complementary clustering algorithms, we identified molecular subtypes in a discovery cohort and validated them in independent external cohorts. The multi-omics classification subsequently guided the screening of high-risk subtypes specific sensitizers to Venetoclax, with candidate efficacy validated through in vitro and in vivo experiments.

Results

We identified three molecularly distinct AML subtypes with unique clinical features, a classification that was subsequently validated in independent external cohorts. Cluster 2 demonstrated the most favorable prognosis, while Cluster 3, characterized by high tumor protein 53 (TP53) mutation frequency and significant immune infiltration, exhibited the poorest outcomes and pronounced resistance to Venetoclax. Multi-omics-guided drug screening revealed that Cluster 3 displays particular sensitivity to both Elesclomol and the clinically available proteasome inhibitor Bortezomib. Through comprehensive in vitro and in vivo validation, we demonstrated that both agents significantly enhance the therapeutic efficacy of Venetoclax. Of particular translational relevance, the Venetoclax-Bortezomib combination leverages an agent with an established safety profile, offering a readily implementable strategy for near-future clinical translation.

Conclusion

Our study establishes a novel multi-omics classification system that provides a robust foundation for investigating biological heterogeneity, elucidating resistance mechanisms, and developing effective combination strategies to achieve personalized therapy in AML.

Schlagwörter

Stichwörter der Autor:innen

Acute myeloid leukemiaVenetoclax resistancemolecular subtypesmulti-omicsprecision medicine

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China.
  • These authors contributed equally to this work and share first authorship.
  • Shaanxi University of Chinese Medicine, Xi'an-Xianyang New Economic Zone, Xi'an 712046, Shaanxi, China.

Zitieren

APA

Yang, R., Feng, H., Zhang, M., Liu, Y., Luo, M., Liu, R., Wang, K., Li, Q., Wang, W., Chen, J., Du, Y., Xiao, J., Yang, B., Niu, F., & He, P. (2026). Multi-omics classification of acute myeloid leukemia guides drug combinations to overcome Venetoclax resistance. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2025.228

Vancouver

Yang R, Feng H, Zhang M, Liu Y, Luo M, Liu R, et al. Multi-omics classification of acute myeloid leukemia guides drug combinations to overcome Venetoclax resistance. Cancer Drug Resistance. 2026. doi:10.20517/cdr.2025.228

BibTeX
@article{Yang2026,
  author = {Yang, Runyu and Feng, Hui and Zhang, Mengyao and Liu, Yi and Luo, Minna and Liu, Ruimin and Wang, Kaiyao and Li, Qijing and Wang, Wenjuan and Chen, Jing and Du, Yue and Xiao, Jiayi and Yang, Bingyu and Niu, Fan and He, Pengcheng},
  title = {Multi-omics classification of acute myeloid leukemia guides drug combinations to overcome Venetoclax resistance},
  journal = {Cancer Drug Resistance},
  year = {2026},
  doi = {10.20517/cdr.2025.228}
}
Kostenlos starten →